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CASE PRESENTATION
A 50-year-old woman recipient of a living-related renal allograft was
referred to the Brigham & Women’s Hospital in Boston for investigation
of deteriorating renal function. She had undergone four normal pregnan-
cies without hypertension or proteinuria. Eighteen years prior to referral,
she had presented to a hospital in another state with nephrotic syndrome,
hematuria, and renal insufficiency. Intravenous pyelography revealed
kidneys of normal size. Serologic tests, including complement studies,
were unremarkable. She declined a renal biopsy.
She was lost to followup for 5 years. She then presented with severe
hypertension and a serum creatinine concentration of 6.8 mg/dl. Intrave-
nous pyelography was again reported as normal and a renal biopsy was
performed. Advanced “renal amyloidosis” was diagnosed on the basis of
extensive deposition of PAS-positive amorphous acellular material in the
glomerular mesangium and capillary walls. No paraprotein was detected in
either serum or urine, and no clinical evidence of extrarenal inflammation
was noted. Her glomerular filtration rate declined rapidly over the ensuing
2 months and hemodialysis was instituted. A review of the original renal
biopsy specimen at an affiliated academic institution failed to confirm the
diagnosis of amyloidosis and concluded that the most likely cause of
end-stage renal disease was systemic hypertension.
Eleven years prior to referral, the patient received a living-related renal
allograft from her mother. The donor is currently asymptomatic and has
normal renal function. The recipient was immunosuppressed with anti-
thymocyte globulin, prednisone, and azathioprine. She was discharged
after a speedy postoperative recovery with a serum creatinine of 1.1 mg/dl.
Five years prior to referral, she developed diabetes mellitus, which was
controlled initially with an oral hypoglycemic agent, but which required
insulin 2 years later. Her serum creatinine at that time was 1.3 mg/dl.
She was admitted to the Brigham & Women’s Hospital for investigation
of uterine bleeding, which ultimately was attributed to fibroids. Assess-
ment of allograft function revealed a serum creatinine of 2.8 mg/dl,
nephrotic-range proteinuria (4.2 g/24 hrs) and 15–20 red blood cells and
20–25 leukocytes/high-power field on microscopy of the urine sediment. A
biopsy of her allograft was striking for recurrence of extensive PAS-
positive, Congo red-negative, amorphous material in the glomerular
mesangium and capillary walls. Immunofluorescence microscopy revealed
IgG and C3. Electron microscopy was notable for the presence of
prominent deposits of randomly arranged extracellular, non-branching
microfibrils in areas corresponding to those with PAS-positive material on
light microscopy. A diagnosis of fibrillary-immunotactoid glomerulopathy
was made.
DISCUSSION
DR. HUGH R. BRADY (Professor of Medicine and Therapeutics,
Mater Miseracordiae Hospital, University College Dublin, Ireland):
More than 200 cases of fibrillary-immunotactoid glomerulopathy
have been reported since its original description by Rosenmann
and Eliakim in 1977 [1]. Fibrillary-immunotactoid glomerulopathy
is an ultrastructural entity characterized by extracellular deposi-
tion of nonbranching microfibrils or microtubules within the
mesangium and capillary walls of renal glomeruli [1–6]. As such,
fibrillary-immunotactoid glomerulopathy represents the most re-
cent addition to a family of glomerulopathies that display, as a
common feature, the presence of fibrillary deposits on electron
microscopy (Table 1). Other important examples are renal amy-
loidosis and the glomerulopathies associated with cryoglobuline-
mias and monoclonal gammopathy. By definition, the fibrillary
deposits of fibrillary-immunotactoid glomerulopathy do not stain
with Congo red or thioflavin T (thus distinguishing them from
amyloid fibrils) and are observed in the absence of circulating
cryoglobulins or paraproteins. Fibrillary-immunotactoid glomeru-
lopathy was detected in 1% of renal biopsy specimens in two large
series, an incidence comparable with anti-glomerular basement
membrane antibody disease [7, 8].
Fibrillary-immunotactoid glomerulopathy is being rapidly ap-
preciated as a “great mimicker” in clinical nephrology and renal
pathology because of its wide range of presentations. Unfortu-
nately, efforts at defining the complete spectrum of manifestations
and the pathophysiology of fibrillary-immunotactoid glomeru-
lopathy have been hampered by a bewildering array of pseudo-
nyms (Table 2) and disagreement concerning diagnostic criteria.
In particular, there is heated debate as to whether fibrillary-
immunotactoid glomerulopathy represents a single entity or two
separate conditions, namely fibrillary glomerulopathy characterized
by smaller (#30 nm in diameter) randomly arranged microfibrils
and a relatively low incidence of malignancy, and immunotactoid
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glomerulopathy typified by the presence of larger (.30 nm in
diameter) microfibrils that are focally organized into parallel
bundles and associated with an increased incidence of malignancy
(Fig. 1). I will discuss the merits and drawbacks of subclassifica-
tion later in this Forum. Specifically, I will argue that insufficient
clinical or pathogenetic grounds exist for subclassification given
present knowledge.
To complicate matters further, there are marked differences of
opinion regarding nomenclature, even among investigators who
agree that data are insufficient to justify subclassification of
fibrillary-immunotactoid glomerulopathy into separate entities.
Some authorities employ the term “fibrillary glomerulopathy” to
denote all the glomerular diseases with extracellular fibrillary
deposits (Table 1). These investigators include amyloid glomeru-
lopathy, cryoglobulinemic glomerulopathy, and light-chain-depo-
sition disease under the broad umbrella of “fibrillary glomeru-
lopathy,” and reserve the term “immunotactoid glomerulopathy”
for the subgroup of patients with idopathic, Congo red-negative
fibrillary deposits in the absence of cryoglobulins or monoclonal
gammopathy. Others prefer to employ the term “glomerular
deposition diseases” to denote a broad family of glomerulopathies
that includes those conditions characterized by extracellular fibril
deposition (Table 1), and reserve the term “fibrillary glomeru-
lopathy” for the subgroup of these patients with Congo red-
negative fibrillary deposits in the absence of cryoglobulins or a
monoclonal gammopathy. To add to this quagmire, many of the
latter authorities then subclassify these patients as having either
fibrillary or immunotactoid glomerulopathy for the reasons I just
outlined.
In this Forum, I deliberately use the broader, all-encompassing
term “fibrillary-immunotactoid glomerulopathy” to describe pa-
tients with glomerular deposition disease characterized by Congo
red-negative extracellular fibrillary deposits in the absence of
cryoglobulins or a paraprotein. This is my attempt to defervesce a
festering and unhelpful controversy. The “umbrella term” refers
to both the fibrillary and immunotactoid ultrastructural variants,
unless specified otherwise. I will argue that it is more prudent to
adhere to this broader terminology until future studies demon-
strate clear clinical differences among variants or define distinct
mechanisms of fibrillogenesis.
Morphologic features
The light microscopy findings associated with fibrillary-immu-
notactoid glomerulopathy are diverse and not diagnostic (Table 3)
[7–44]. Common features include mesangial hypercellularity,
mesangial expansion with amorphous PAS-positive material, and
thickening of the glomerular capillary wall. The overall appear-
ance can resemble mesangioproliferative, membranoproliferative,
focal or diffuse proliferative, and membranous glomerulopathy.
Crescents are common, particularly among patients with the
fibrillary variant (;25%). Most specimens display some arterio-
sclerosis [7, 8]. Interstitial inflammation and fibrosis as well as
tubular atrophy are common in patients with extensive glomerular
disease [7, 8].
Immunofluorescence microscopy typically reveals IgG and C3
in a distribution that corresponds with the pathognomonic depos-
its of microfibrils and microtubules (Table 3) [7–37]. Positive
staining for IgM and IgA is less common (;50% and ;25%,
respectively) and characteristically weak. Fibrin is usually de-
tected in crescents, as with other forms of crescentic glomerulo-
nephritis. When fibrillary deposits are abundant in the glomerular
capillary wall, immunofluorescence microscopy for IgG can dem-
onstrate prominent pseudolinear staining that may be mistaken
for anti-glomerular basement membrane disease by less-experi-
enced observers. Among patients with the fibrillary variant, IgG4
tends to be the dominant subclass (virtually 100% of cases) and
overshadows weak staining for IgG1 (;15%) and absent IgG2
and IgG3 [8]. Both kappa and lambda light chains are detected in
more than 75% of patients with this variant, indicating polyclonal
deposition of IgG [7, 8]. Although more detailed systematic
analyses of IgG subtypes are required for the immunotactoid
variant, the IgG4 subclass appears to be less dominant than with
the fibrillary variant: however, here again, IgG deposition is
typically polyclonal (;66% of cases) [7].
Diagnosis of fibrillary-immunotactoid glomerulopathy hinges
on electron microscopy. As I said, two major ultrastructural
patterns are observed. The majority of patients have deposits of
microfibrils of 15–25 nm in diameter (fibrillary variant). These
microfibrils are larger than amyloid fibrils, the latter typically
being 6–10 nm in diameter, and are arranged randomly in the
glomerular tuft (Fig. 1). Within individual patients, fibrils tend to
be of uniform diameter, although some admixture has been noted
[8]. Fibrils are typically found in the mesangial areas but also can
be distributed in the subendothelial and subepithelial spaces and
across the basement membrane. Although not usually seen under
routine magnification, a lumen is commonly observed in microfi-
brils of patients with the fibrillary variant under higher magnifi-
cations; thus many, if not all, microfibrils are microtubules [5]. A
minority of patients with fibrillary-immunotactoid glomerulopathy
have larger microfibrils (.30 nm in diameter, immunotactoid
Table 1. Diseases associated with deposition of extracellular non-
branching fibrils within glomeruli
Congo red positive
Amyloidosis
AL amyloidosis (derived from light chains)
AA amyloidosis (derived from serum amyloid protein)
Congo red negative
Cryoglobulinemias
Type I (monoclonal)
Type II (mixed, one being monoclonal)
Type III (mixed, both polyclonal)
Monoclonal gammopathies
Benign monoclonal gammopathy
Multiple myeloma
Light-chain deposition disease
Chronic lymphocytic leukemia
Fibrillary-immunotactoid glomerulopathy
Familial
Acquired
Miscellaneous (SLE, diabetes mellitus, pre-eclampsia)
Table 2. Synonyms for fibrillary-immunotactoid glomerulopathy
Fibrillary glomerulopathy
Fibrillary nephritis
Fibrillary glomerulonephritis
Immunotactoid glomerulopathy
Amyloid-like glomerulopathy
Non-amyloidotic fibrillary glomerulopathy
Congo red-negative amyloidosis-like glomerulopathy
Amyloid stain-negative microfibrillary glomerulopathy
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variant), which typically have a visible lumen (microtubules) and
are focally arranged in parallel bundles (Fig. 1). Effacement of
foot processes of visceral epithelial cells is noted in most patients
with fibrillary-immunotactoid glomerulopathy [7, 8]. Although
extremely rare, extraglomerular fibril deposits have been reported
in the walls of peritubular capillaries and in basement membranes
of renal tubules [10, 14]. Immune-complex-type dense deposits
are characteristically absent; however, fibrils are frequently found
amid electron-dense material, suggesting the presence of other
abnormal materials [2]. Some investigators have argued that the
fibrillary and immunotactoid ultrastructural patterns result from
different pathophysiologic processes and/or portend different
clinical courses [4, 6, 7]. As I will discuss in a moment, the validity
of this subclassification is disputed [3, 5].
Clinical features
Patients with fibrillary-immunotactoid glomerulopathy present
with proteinuria, hematuria, hypertension, and renal insufficiency
that progresses over months to years [2–6]. The vast majority of
cases are idiopathic and occur in the absence of other systemic
diseases. Serum complement levels (C3, C4) typically are normal,
and assays for anti-nuclear antibodies, anti-neutrophil cytoplasmic
antibodies, anti-glomerular basement membrane antibodies, and
Fig. 1. Typical ultrastructural appearance of fibrillary-immunotactoid glomerulopathy. Left panel shows randomly arranged smaller microfibrils,
typical of the fibrillary variant. Right panel shows more organized thicker microtubules, typical of the immunotactoid variant. (Micrographs courtesy of
Dr. Helmut Rennke, Brigham & Women’s Hospital, Boston, Massachusetts.)
Table 3. Features of fibrillary-immunotactoid glomerulopathy on light
and immunofluorescence microscopya
Patients, %
Light microscopy
Mesangial hypercellularity and matrix expansion 95
Thickening of the glomerular capillary wall 95
Diffuse proliferation 40
Crescent formation 19
Glomerular obsolescence 23
Arteriosclerosis 75
Interstitial fibrosis and tubular atrophy variable
Interstitial leukocyte infiltrate variable
Immunofluorescence microscopy
IgG (usually IgG4) 97
IgM 61
IgA 37
C3 97
Kappa 96
Lambda 84
a Data from Refs. 7 and 8, with permission.
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rheumatoid factor are negative [2–8], with occasional exceptions
[7, 36, 45- 47].
To define the clinical features of fibrillary-immunotactoid glo-
merulopathy in more detail, we recently reviewed the case records
of 25 patients (referred to our institutions between 1986 and 1993)
whose renal biopsy specimens revealed prominent Congo red-
negative extracellular fibrillary glomerular deposits in the absence
of detectable circulating cryoglobulins [48]. In addition, we ana-
lyzed the clinical presentations of 161 cases of fibrillary-immuno-
tactoid glomerulopathy reported previously, as identified by a
computerized search of the MEDLINE database from 1977
through June 1994 [1, 4, 7–37]. We sought to determine whether
the fibrillary and immunotactoid variants differ in their clinical
features. Because pathologists’ criteria for subclassification can
vary, we performed separate analyses in which patients were
classified as having the fibrillary or immunotactoid variant on the
basis of either fibril diameter (fibrillary # 30 nm, immunotac-
toid . 30 nm) or arrangement (fibrillary, random; immunotac-
toid, focally organized). Patients with cryglobulinemia, diabetes
mellitus, or systemic lupus erythematosus, all of which are poten-
tial causes of Congo red-negative fibrillary glomerular deposits,
were excluded. For purposes of analysis, renal insufficiency was
defined as a serum creatinine of $ 1.5 mg/dl, hypertension as
systemic arterial blood pressure of $ 140/90 mm Hg, proteinuria
as dipstick-positive proteinuria or urinary protein excretion of $
150 mg/24 hr, and nephrotic syndrome as urinary protein excre-
tion of $ 3.5 g/24 hr.
Fibrillary-immunotactoid glomerulopathy can present over a
wide range of ages and has been reported in patients as young as
10 years and as old as 81 years (Table 4). Most authors note a
slight female preponderance among patients with the fibrillary
ultrastructural variant and a slight male preponderance among
patients with the immunotactoid variant (Table 4) [7–14]. Whites
predominate among patients with the fibrillary variant; this pre-
ponderance exceeds the white:black ratio in renal biopsy popula-
tions overall [7, 8]. The number of patients reported with the
immunotactoid variant is too small to allow meaningful comment
regarding race. All patients have proteinuria at presentation,
usually in the nephrotic range. The majority of patients also have
microscopic hematuria (;70%), hypertension (;65%), and renal
insufficiency (;50%). The clinical features do not differ signifi-
cantly among patients with the fibrillary and immunotactoid
variants and do not support subclassification on the basis of
clinical presentation alone.
In an attempt to define clinical features at presentation that
predict the rate of decline of glomerular filtration rate (GFR), we
stratified 25 patients presenting to our institutions according to
the slope of 1/serum creatinine (1/Cr) versus time [48]. The
groups did not differ in age, prevalence of hematuria or protein-
uria, or level of serum creatinine at presentation. As with most
glomerulopathies, the presence of nephrotic syndrome and hyper-
tension at presentation tended to predict a more rapid decline of
GFR. The results of one large series suggest that the rate of
progression of renal insufficiency is faster in patients with the
fibrillary variant [7]; this interesting observation warrants further
investigation.
Fibrillary-immunotactoid glomerulopathy has been reported in
association with a variety of systemic diseases, including lympho-
proliferative malignancy, gastric adenocarcinoma, metastatic ad-
enocarcinoma of the liver, mixed connective tissue disease,
Sjo¨gren’s syndrome, and leukocytoclastic vasculitis (Table 5).
Occasional association with infections such as hepatitis C also has
been noted [46, 47]. The strength of association between fibrillary-
immunotactoid glomerulopathy and malignancy is the subject of
heated debate [2–6]. Much of the controversy focuses on whether
patients with Congo red-negative fibrillary deposits and a circu-
lating paraprotein should be classified as having “fibrillary-immu-
notactoid glomerulopathy” or whether they have a form of
light-chain-deposition disease and should be excluded from anal-
yses. To explore this issue further, we reviewed the incidence of
malignancy in 186 patients with fibrillary-immunotactoid glo-
merulopathy following inclusion and exclusion of patients with
monoclonal gammopathy (Table 6) [48]. When patients with a
circulating or urinary paraprotein were included, the presence of
a paraprotein was accepted as evidence of malignancy. Under the
latter circumstances, the incidence of malignancy was markedly
higher in patients with the immunotactoid (;33%) as compared
with the fibrillary (;7%) variant. In contrast, when patients with
Table 4. Demographics and presenting clinical features of 186 patients with fibrillary-immunotactoid glomerulopathy
Clinical features
Fibrillary varianta Immunotactoid variantb
Fibril diameterc Fibril arrangementc Fibril diameterc Fibril arrangementc
Number of patientsd 172 164 12 22
Male:female 1.0:1.3 1.0:1.3 1.4:1.0 2.6:1.0
Age range 10–81 10–81 12–68 10–68
Race (white:black) 9:1 (n 5 70) 9:1 (n 5 70) —e —e
Hypertension 85/126 (67%) 81/118 (69%) 5/11 (45%) 11/13 (85%)
Hematuria 109/153 (71%) 103/146 (70%) 7/11 (64%) 15/20 (75%)
Proteinuria 172/172 (100%) 164/164 (100%) 12/12 (100%) 22/22 (100%)
Nephrotic syndrome 94/133 (71%) 87/125 (70%) 9/11 (82%) 18/21 (86%)
Renal insufficiency 78/144 (54%) 73/136 (54%) 5/12 (42%) 10/22 (45%)
a From Refs. 1, 7–32.
b From Refs. 1, 7, 9–11, 18, 29–37.
c To determine whether the fibrillary (F) and immunotactoid (IT) variants have different clinical features, patients were subdivided according to the
diameter (F # 30 nm, IT . 30 nm) or arrangement (F, random; IT, focally organized) of microfibrils and microtubules. In general, these different
criteria identified the same subpopulations of patients (.90% concordance).
d Fibril size was not reported in two patients. Study population consists of 25 patients presenting to the Brigham & Women’s Hospital and 161 patients
reported previously in the literature.
e Insufficient data for interpretation. (Modified with permission from Ref. 48.)
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a paraprotein were excluded, the incidence of malignancy was
similar in each setting (#7%).
Immunosuppressive therapy and role of transplantation
Approximately 50% of patients with fibrillary-immunotactoid
glomerulopathy develop end-stage renal failure within 4 years of
diagnosis [2–6, 48]. The published information on the influence of
conventional immunosuppressive therapy on this process is
scanty. Several uncontrolled reports suggest that corticosteroids,
cytotoxic agents, and plasma exchange confer limited, if any,
benefit [1, 17, 19, 29, 48, 49]. This marginal renoprotection must
be balanced against the well-documented risks of drug toxicity.
Experience with renal transplantation is sparse. In our series, 4
patients with the fibrillary ultrastructural variant received 5 renal
allografts (one patient undergoing transplantation twice) and
were followed for 4 to 11 years (Table 7) [48]. Whereas recurrence
of fibrillary deposits was noted in all patients undergoing biopsy of
allografts post transplant, the rate of decline of GFR was always
slower with allografts than with native kidneys. Indeed, two
allografts are functioning normally, as determined by serum
creatinine, 4 and 8 years after transplantation. Furthermore, other
allografts have maintained sufficient function to avoid dialysis for
6 to 11 years, even in the presence of biopsy-proven recurrence of
fibrillary deposits. Other investigators report similar experiences
and note satisfactory allograft function for 5 years or more in most
patients despite recurrence of fibril deposition in over 50% of
cases [12, 16, 32, 38]. Thus, transplantation is a viable option for
renal replacement therapy in patients with fibrillary-immunotac-
toid glomerulopathy, particularly if the rate of decline of GFR in
the native kidney had been relatively slow. These results are in
stark contrast to those reported for primary amyloidosis, in which
allograft and patient survival are notoriously poor [5, 6, 39].
Fibril composition and mechanisms of fibrillogenesis
The prominence of IgG and C3 on immunofluorescence mi-
croscopy in a pattern that corresponds with fibrillary deposits on
electron microscopy raises the possibility that fibrils are immuno-
logic in origin [2–8]. The observation that IgG4 is the dominant
subclass in patients with the fibrillary variant is also intriguing
given that this subclass usually accounts for ,5% of circulating
IgG [8]. More detailed ultrastructural immunohistochemical lo-
calization studies using protein A gold immunoelectron micros-
copy have confirmed that the IgG and C3 co-localize with the
fibrils [15]. In addition, the latter technique demonstrated amyloid
P component in association with many fibrils [15]. In aggregate,
these studies indicate that IgG and C3 are potential precursor
molecules for fibrillogenesis in many cases. Amyloid P component
also might form part of some fibrils, but clearly not in a configu-
ration (that is, a beta-pleated sheet) that confers Congo red
positivity.
Several lines of evidence suggest that precursor molecules other
than IgG and C3 also contribute to fibril formation, and point to
serum-derived fibronectin as an important component. Immuno-
fluorescence and immunohistochemical studies reveal scant or
absent IgG and C3 in some patients with the typical clinical and
electron microscopic features of fibrillary-immunotactoid glo-
merulopathy [40, 42]. In two kindreds of familial fibrillary-
immunotactoid glomerulopathy, fibrillary deposits showed intense
staining for fibronectin, but not for other extracellular matrix
proteins such as collagens I, III, IV, or V, heparan sulfate
proteoglycan, or tenascin [42–44]. Additional studies in one
kindred demonstrated that fibrillary deposits also stained posi-
tively with monoclonal antibody IST-4, which recognizes both cell-
and plasma-derived fibronectin, but not monoclonal antibody
IST-9, which detects only cell-derived fibronectin [42]. These
findings implicate plasma-derived fibronectin as a precursor mol-
ecule in fibrillogenesis. In support of the latter hypothesis, a
serum fibrillar cryoprecipitate was recently described from a
patient with fibrillary-immunotactoid glomerulopathy that formed
on prolonged storage at 4oC and consisted of immunoglobulins,
heavy chains g and m, light chains k and l, and fibronectin, as
determined by Western blot and amino-acid-sequence analysis
[41]. Immunohistochemical analysis of the patient’s renal biopsy
specimen disclosed a similar phenotype [41]. The frequent recur-
rence of fibrillary deposits in renal allografts lends credence to the
notion that the fibrils are derived from plasma-derived proteins
[48]. Korbet et al have speculated that microfibrils form along the
glomerular filtration barrier as a consequence of their biophysical
properties and the physiologic ultrafiltration [5]. The one or more
mechanisms by which deposited fibrils in turn perturb glomerular
function have not been elucidated.
In short, it appears that multiple mechanisms of fibrillogenesis
can lead to the ultrastructural entity known as fibrillary-immuno-
tactoid glomerulopathy. By extension, these observations caution
against subclassification of fibrillary-immunotactoid glomerulopa-
thy on the basis of ultrastructure alone.
Are the fibrillary and immunotactoid ultrastructural variants
distinct clinicopathologic entities?
Should one subclassify patients with fibrillary-immunotactoid
glomerulopathy as having either fibrillary glomerulopathy or
immunotactoid glomerulopathy, as suggested by some investiga-
tors? I contend that it is premature to do so for general reasons.
First, these ultrastructural variants present with similar clinical
features (Table 4). Second, the purported higher incidence of
lymphoproliferative malignancy in patients with the immunotac-
toid variant depends largely on arbitrary diagnostic criteria (that
is, inclusion or exclusion of patients with a paraprotein) (Table 6).
Third, biochemical and pathogenetic information is as yet insuf-
ficient to justify subclassification on the basis of fibril composition
or mechanisms of fibrillogenesis. Indeed, the current evidence
suggests that fibrillary-immunotactoid glomerulopathy is an ultra-
structural end point that results from diverse fibrillogenetic
Table 5. Some diseases associated with fibrillary-immunotactoid
glomerulopathya
Neoplasia
Monoclonal gammopathy
Chronic lymphocytic leukemia
Non-Hodgkin’s and B-cell lymphoma
Gastric adenocarcinoma
Metastatic adenocarcinoma of liver
Miscellaneous
Mixed connective tissue disease
Sjo¨gren’s syndrome
Hepatitis C infection
Treated tuberculosis
Leukocytoclastic vasculitis
a Most associations represent case reports.
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mechanisms including processing of immune components, dys-
regulated fibronectin homeostasis, and formes fruste of cryoglob-
ulinemia and light-chain-deposition disease. Finally, it would be
folly to subclassify patients on the basis that the variants “look
different.” Pathologically, more detailed ultrastructural analysis
using high-power electron microscopy demonstrates that many of
the microfibrils of the fibrillary variant are indeed microtubules,
albeit narrower than those of the immunotactoid variant [5].
Furthermore, whereas the narrow microfibrils of the fibrillary
variant tend to be randomly arranged and the thicker microtu-
bules of the immunotactoid variant more organized, these pat-
terns can overlap [5]. Protein biochemistry and biopolymer sci-
ence are replete with examples of marked changes in the tertiary
configuration of proteins induced by minor alterations in amino
acid composition and the physical characteristics of the milieu
exterior (elegantly discussed in Refs. 5 and 50). In purely engi-
neering terms, shorter, narrower tubes would be expected to
assume a more random arrangement in a confined space than
would longer, thicker tubes, which should assume a more orga-
nized parallel arrangement (try this with drinking straws in a
cup!). In addition to cautioning against premature subclassifica-
tion, I also contend that it is preferable to avoid nomenclature
that prematurely suggests mechanisms of fibrillogenesis, such as
“immunotactoid,” particularly in light of recent evidence that
many fibrils do not contain immune components.
Where, then, does fibrillary-immunotactoid glomerulopathy
belong among the major categories of glomerular disease? It
seems reasonable to consider fibrillary-immunotactoid glomeru-
lopathy as a form of glomerular deposition disease, of which four
types are dominated by the presence of extracellular fibrillary
deposits: (1) Congo red-positive, amyloid-associated fibrillary
glomerulopathy, (2) Congo red-negative fibrillary glomerulopathy
with cryoglobulinemia, (3) Congo red-negative fibrillary glomeru-
lopathy with monoclonal gammopathy, and (4) Congo red-nega-
tive idiopathic fibrillary glomerulopathy (that is, without detect-
able cryoglobulins or monoclonal gammopathy) [48]. From a
clinical viewpoint, the finding of Congo red-negative extracellular
fibrillary deposits on renal biopsy should prompt a search for
monoclonal gammopathy or cryoglobulins. Future studies that
unravel the mysteries of glomerular fibrillogenesis and decipher
the mechanism(s) by which fibril deposition perturbs glomerular
function should yield exciting new insights into the pathophysiol-
ogy of glomerular disease.
QUESTIONS AND ANSWERS
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston, Massachusetts, USA): Was the first biopsy from
today’s patient reviewed at the Brigham & Women’s Hospital?
Second, assuming one excludes cryoglobulinemia and parapro-
teinemia, what circulating factor accounts for the deposition, and
why can’t we find it?
PROF. BRADY: Review of the original renal biopsy at the
Brigham and Women’s Hospital revealed nonbranching, extracel-
lular, randomly arranged microfibrils typical of fibrillary-immuno-
tactoid glomerulopathy. As a more general comment, the increas-
ing recognition of this entity reinforces the need for routine
electron microscopic analysis of all renal biopsies, particularly
given the ability of fibrillary-immunotactoid glomerulopathy to
mimic most major morphologic patterns on light and immunoflu-
orescence microscopy.
With regard to the role of circulating factors in the pathogen-
esis of fibrillary-immunotactoid glomerulopathy, the ultrastruc-
tural similarities between this entity and other deposition diseases
such as cryoglobulinemia, light-chain deposition disease, and
amyloid support the contention that the fibrils are derived from
Table 6. Association of fibrillary-immunotactoid glomerulopathy with malignancy
Patients with malignancy/Total number of patients (% total)
Fibrillary varianta Immunotactoid variantb
Diameterc Arrangementc Diameterc Arrangementc
Analysis includes patients with
monoclonal gammopathyd
12/172 (7%) 8/164 (5%) 4/12 (33%) 9/22 (41%)
Analysis excludes patients with
monoclonal gammopathyd
5/165 (3%) 5/160 (3%) 0/8 (0%) 1/14 (7%)
a From Refs. 1, 7–32. Two major studies (10, 11) of the fibrillary variant excluded patients with evidence of monoclonal gammopathy, thereby
potentially skewing this association in favor of the immunotactoid variant. (Modified with permission from Ref. 48.)
b From Refs. 1, 7, 9–11, 18, 29–37.
c As with Table 2, fibrillary (F) and immunotactoid (IT) variants were defined according to the diameter (F # 30 nm, IT . 30 nm) or arrangement
(F, random; IT, focally organized) of microfibrils and microtubules.
d Fibril size not reported in two patients. As with Table 4, study population consists of 25 cases presenting to the Brigham & Women’s Hospital and
161 reported in the literature. In this analysis, the presence of a circulating or urinary paraprotein was accepted as evidence of a lymphoproliferative
neoplasia.
Table 7. Outcome of five cadaveric renal transplants in 4 patients with
fibrillary-immunotactoid glomerulopathya
Patientb
Slope-
nativec
Slope-
allograft
Followup
(yrs)
Recurrence
in graft Immunosuppression
1 0.850 0.0 4 pd CsA, Pred, Aza
2 0.150 0.050 7 yes CsA, Pred, Aza
0.068 6 yes CsA, Aza
3 0.100 0.0 8 pd Pred, Aza
4 0.102 0.060 11 yes ATG, Pred, Aza
a Modified with permission from Ref. 48.
b All patients had fibrillary variant, as defined by fibril diameter and
morphology in Table 4. Slope denotes 1/serum creatinine versus time.
Abbreviations are: Aza, azathioprine; CsA, cyclosporine A; Pred, pred-
nisone; ATG, antithymocyte globulin.
c Native kidney: mean slope 6 SE 0.301 6 0.18 (n 5 4). Allograft: mean
slope 6 SE 0.036 6 SE 0.01 (n 5 5).
d p Denotes that the allograft was not biopsied.
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circulating factors. The “deposition hypothesis” is further sup-
ported by observations that fibrils usually recur in renal allografts;
that serum-derived immunoglobulin and fibronectin are strongly
associated with, and are probably a component of, fibrils in many
patients; and that patients without a circulating cryoglobulin, as
determined by conventional laboratory assays, have been demon-
strated to have fibronectin-containing cryoglobulins on more
detailed study.
DR. PETER GARRETT (Consultant Nephrologist, Omagh General
Hospital, Omagh, Ireland): Given that many cases of mixed
cryoglobulinemia appear to be caused by chronic hepatitis C
infection, have studies of fibrillary-immunotactoid glomerulopa-
thy systematically sought evidence for hepatitis C?
PROF. BRADY: Hepatitis C was excluded in many published
cases of fibrillary-immunotactoid glomerulopathy. I am, however,
aware of one case of this glomerulopathy in a hepatitis C-infected
individual in the absence of circulating cryoglobulin [46]. Again,
this observation raises the possibility that some patients with
fibrillary-immunotactoid glomerulopathy have a forme fruste of
cryoglobulinemia.
DR. JOHN DONOHOE (Consultant Nephrologist, Beaumont Hos-
pital and Mater Miseracordiae Hospital, Dublin): As a followup to
discussions on the possible role of cryoglobulin-like substances, do
you recommend plasmapheresis or immunoadsorption in fibril-
lary-immunotactoid glomerulopathy? Second, might these treat-
ments yield additional “plasma factors” that could be used to
emulate the human condition in animal models?
PROF. BRADY: Plasmapheresis and immunoadsorption have not
been evaluated critically as treatments for fibrillary-immunotac-
toid glomerulopathy. In the absence of rigorously controlled data,
I do not recommend these interventions because the concentra-
tion of cryoglobulin-like factors in serum is likely very low, and the
rate of deterioration of renal function, and probably the rate at
which fibrils are formed, is usually slow. Plasmapheresis is gener-
ally ineffective under these circumstances, even in classic mixed
essential cryoglobulinemia (reviewed in Ref. 51). Furthermore,
the side effects of plasmapheresis are significant and must be
weighed against this marginal benefit [51]. Plasmapheresis might
be a useful experimental tool for isolating pathogenetic circulating
factors with a view to developing an animal model, particularly
given the recent identification of fibronectin-containing cryo-
globulins in some patients [41].
DR. YVONNE O’MEARA (Consultant Nephrologist, Mater Misera-
cordiae Hospital and Senior Lecturer in Medicine, University College
Dublin): Is recurrence of fibril deposition in renal allografts a
universal finding in patients with fibrillary-immunotactoid glo-
merulopathy, and could you speculate on the mechanism by which
fibril deposition induces proteinuria?
PROF. BRADY: Fibrils were observed in all patients in our series
who were biopsied post transplant [48], and this appears to be the
experience of most other clinicians, as judged from the handful of
short reports addressing this issue [12, 16, 32, 38]. With regard to
the mechanism of proteinuria, it is likely that a number of factors
act in concert to perturb the glomerular filtration barrier for
protein. First, IgG4 can activate the alternative pathway of
complement, and the latter is a well-defined mediator of glomer-
ular injury. Second, gross disruption of basement membrane
architecture is observed in some patients as a consequence of
transmembrane fibril deposition. Third, it is possible, although
unproven, that the fibrils further perturb the integrity of the
filtration barrier either directly by interfering with anchoring of
visceral epithelial cells to basement membrane or indirectly
through activation of resident glomerular cells and local release of
proteases and other inflammatory mediators. It is noteworthy that
effacement of the foot processes of visceral epithelial cells is a
common feature on electron microscopy. This finding supports a
role for podocyte injury.
PROF. BRIAN A. KEOGH (Consultant Nephrologist, Meath Hospi-
tal, and Professor of Renal Medicine, Trinity College, Dublin): Is
fibril deposition limited to the kidney in all cases, or are there
examples of systemic involvement?
PROF. BRADY: Fibril deposition is limited to the kidney in the
vast majority of cases, although extrarenal deposition has been
reported in lung or hepatic tissue in two cases [21, 49]. This
pattern differs markedly from deposition diseases such as amyloid
and cryoglobulinemia, and suggests that the components of fibrils
in fibrillary-immunotactoid glomerulopathy have unusual tropism
for glomerular ligands or that fibril formation is exquisitely
dependent on the unique physiochemical milieu in glomerular
extracellular fluid that results from glomerular filtration.
PROF. JOHN M. FITZPATRICK (Professor of Surgery, University
College Dublin, and Consultant Urologist, Mater Miseracordiae
Hospital): If one excludes patients with paraproteinemia, is the
association between fibrillary-immunotactoid glomerulopathy and
malignancy a chance association rather than a definite one? By
extension, how aggressively should you investigate these patients
for malignancy?
PROF. BRADY: Our analysis demonstrated a lower incidence of
malignancy when patients with paraproteins were excluded (Table
6). Under the latter circumstances, the incidence of malignancy
was similar among patients with the fibrillary and immunotactoid
variants. The tumors were indeed quite diverse, and the associa-
tion could be one of chance. Nevertheless, it would seem prudent
to screen patients presenting with fibrillary-immunotactoid glo-
merulopathy for a circulating and urinary paraprotein, and to
assess them for other malignancy by astute clinical examination,
routine hematologic and biochemical testing, chest x-ray, and
fecal occult bloods, and possibly with abdominal ultrasound and
colonoscopy.
DR. KIERAN SHEAHAN (Consultant Pathologist, St. Vincent’s
Hospital, Dublin): The much-quoted incidence of 1% is derived
from two large U.S. centers. It is worth noting that the diagnosis
of fibrillary-immunotactoid glomerulopathy was made in 2% of
our renal biopsies over the past 5 years. Thus, the entity is at least
as common in a European setting.
DR. ANTHONY DORMAN (Consultant Pathologist, Beaumont Hos-
pital, Dublin): Our experience has not been as dramatic. We
diagnosed only two cases of fibrillary-immunotactoid glomeru-
lopathy among 360 cases of nephrotic syndrome seen at our
institution between 1985 and 1995. Amyloid glomerulopathy was
much more common, accounting for 27 cases.
DR. EOIN GAFFNEY (Consultant Pathologist, St. James’s Hospital,
Dublin): I concur that minor changes in the amino acid composi-
tion of a protein can result in major conformational changes.
Thus, your caution against subclassifying on the basis of ultra-
structural appearance is well taken. Indeed, it is possible that
similar mechanisms of fibrillogenesis lead to fibrillary-immuno-
tactoid and amyloidotic glomerulopathies, as relatively minor
differences in amino acid composition also might determine why
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one type of fibril assumes a beta-pleated sheet conformation and
stains with Congo red, and the other type does not.
DR. DERMOT MURNAGHAN (Consultant Nephrologist, Cork Uni-
versity Hospital, Cork, Ireland): I also agree that whereas it is
important clinically to distinguish between amyloid and non-
amyloid fibrillary glomerulopathies, one should be cognizant of
the fact that similar pathogenetic mechanisms can underlie these
conditions.
DR. DAVID C. COTTELL (Electron Microscopy Unit, University
College Dublin): Has too much emphasis been placed on fibril
diameter in the past for subclassification of the fibrillary glomeru-
lopathies?
PROF. BRADY: In a word, yes. In a recent elegant dissertation on
this topic, Korbet et al highlighted the wide range of fibril
diameter, even within the fibrillary and immunotactoid variants
[5]. Our experience is similar. I contend that subclassification of
fibrillary-immunotactoid glomerulopathy into fibrillary and immu-
notactoid variants should be resisted until it is conclusively
demonstrated that these variants have different clinical features
or different mechanisms of fibrillogenesis.
DR. GEORGE MELLOTTE (Consultant Nephrologist, St. James’s
Hospital, Dublin): Is there variation of microfibril or microtubule
size between families with hereditary forms of fibrillary-immuno-
tactoid glomerulopathy?
PROF. BRADY: The microfibrils in patients from the two largest
reported kindreds were 10–12 nm and 12–16 nm in diameter and
were randomly arranged [42, 44]. Further analysis of these
families should shed light on the mechanisms of fibrillogenesis. It
is interesting that haplotype analysis of one of these families with
large fibronectin-containing deposits [44] excluded fibronectin
(and indeed villin and desmin) as causative genes [52]. This
finding suggests that a defect in another gene perturbs fibronectin
homeostasis and triggers fibril formation.
PROF. FRANCIS P. MULDOWNEY (Consultant Nephrologist, St.
Vincent’s Hospital, and Professor of Experimental Medicine, Univer-
sity College Dublin): Taking out patients with cryoglobulinemia or
paraproteinemia, is fibrillary-immunotactoid glomerulopathy re-
ally a distinct disease? The clinical presentation, natural history,
and response to therapy are relatively nonspecific.
PROF. BRADY: In the absence of unique clinical features and
detailed knowledge of the mechanisms of fibrillogenesis, fibril-
lary-immunotactoid glomerulopathy should be considered an
ultrastructural entity defined on electron microscopy. Again, I
contend that it is premature to consider fibrillary-immunotactoid
glomerulopathy a distinct disease. Indeed, the initial studies on
the composition of fibrils and mechanisms of fibrillogenesis
summarized in my discussion suggest that fibrillary-immunotac-
toid glomerulopathy is an ultrastructural end point induced by a
variety of different pathogenetic processes, much in the same way
that diverse hemodynamic, toxic, and immune insults can trigger
the light microscopic morphologic pattern of focal segmental
glomerulosclerosis.
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